BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 21695633)

  • 1. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment screening using X-ray crystallography.
    Davies TG; Tickle IJ
    Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using computational techniques in fragment-based drug discovery.
    Desjarlais RL
    Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based drug design.
    Feyfant E; Cross JB; Paris K; Tsao DH
    Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based approaches and computer-aided drug discovery.
    Rognan D
    Top Curr Chem; 2012; 317():201-22. PubMed ID: 21710380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in fragment-based drug discovery platforms.
    Orita M; Warizaya M; Amano Y; Ohno K; Niimi T
    Expert Opin Drug Discov; 2009 Nov; 4(11):1125-44. PubMed ID: 23480433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational medicinal chemistry in fragment-based drug discovery: what, how and when.
    Rabal O; Urbano-Cuadrado M; Oyarzabal J
    Future Med Chem; 2011 Jan; 3(1):95-134. PubMed ID: 21428828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences in fragment-based drug discovery.
    Murray CW; Verdonk ML; Rees DC
    Trends Pharmacol Sci; 2012 May; 33(5):224-32. PubMed ID: 22459076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-world phenomena in chemical library networks: application to fragment-based drug discovery.
    Tanaka N; Ohno K; Niimi T; Moritomo A; Mori K; Orita M
    J Chem Inf Model; 2009 Dec; 49(12):2677-86. PubMed ID: 19961207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.